Terutroban is primarily investigated for its potential therapeutic applications in cardiovascular diseases. It functions as a thromboxane receptor antagonist, which means it can inhibit the effects of thromboxane, a substance involved in blood clotting and the constriction of blood vessels. This makes it a candidate for preventing thrombosis, a condition where blood clots block veins or arteries, which can lead to heart attacks or strokes. Research has explored its use in patients with a history of ischemic stroke or other arterial diseases to assess its efficacy in reducing the recurrence of such events. Additionally, its antiplatelet properties are studied for managing atherosclerosis, where plaque builds up in the arteries, potentially improving blood flow and reducing the risk of cardiovascular complications.